Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach

Genome Biology

Volumn 16, Issue 1, 2015, Pages

  Castellanos Martín, Andrés ^a,b,j   Castillo Lluva, Sonia ^a,b   Sáez Freire, María del Mar ^a,b,c   Blanco Gómez, Adrián ^a,b   Hontecillas Prieto, Lourdes ^a,b   Patino Alonso, Carmen ^b,c   Galindo Villardon, Purificación ^b,c   Pérez del Villar, Luis ^b,c   Martín Seisdedos, Carmen ^b,d   Isidoro Garcia, María ^b,d   Abad Hernández, María del Mar ^b,c   Cruz Hernández, Juan Jesús ^a,b,d,e   Rodríguez Sánchez, César Augusto ^b,d   González Sarmiento, Rogelio ^a,b,e   Alonso López, Diego ^a,b,f   De Las Rivas, Javier ^a,b,f   García Cenador, Begoña ^b,c   García Criado, Javier ^b,c   Lee, Do Yup ^g   Bowen, Benjamin ^h   Reindl, Wolfgang ^h   Northen, Trent ^h   Mao, Jian Hua ⁱ   Pérez Losada, Jesús ^a,b   more..

^a CSIC   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f Centro de Investigacion del Cancer   (Spain)

^g Kookmin University   (South Korea)

^h LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; TUMOR MARKER; AKT1 PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE RESISTANCE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; FEMALE; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; INTRACELLULAR SIGNALING; LIFESPAN; LIVER CELL; LIVER TUMOR; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPIC VARIATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE TRAIT LOCUS; SITE DIRECTED MUTAGENESIS; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TUMOR DIFFERENTIATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, GENETIC; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SYSTEMS BIOLOGY;

EID: 84939129793     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-015-0599-z     Document Type: Article

References (57)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol. 2009;33:315-8.
2. Carmichael A, Sami AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol. 2003;29:475-9.
3. Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010;28:1813-20.
4. Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet. 1995;57:1284-97.
5. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56-68.
6. Vidal M, Cusick ME, Barabasi AL. Interactome networks and human disease. Cell. 2011;144:986-98.
7. Balmain A. Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell. 2002;108:145-52.
8. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer. 2010;10:353-61.
9. Galvan A, Ioannidis JP, Dragani TA. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. Trends Genet. 2010;26:132-41.
10. McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141:210-7.
11. Hunter KW, Crawford NP. The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu Rev Genet. 2008;42:131-41.
12. Quigley D, Balmain A. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet. 2009;10:651-7.
13. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.
14. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, et al. Modeling precision treatment of breast cancer. Genome Biol. 2013;14:R110.
15. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A. 1992;89:10578-82.
16. Ullrich RL, Bowles ND, Satterfield LC, Davis CM. Strain-dependent susceptibility to radiation-induced mammary cancer is a result of differences in epithelial cell sensitivity to transformation. Radiat Res. 1996;146:353-5.
17. Rowse GJ, Ritland SR, Gendler SJ. Genetic modulation of neu proto-oncogene-induced mammary tumorigenesis. Cancer Res. 1998;58:2675-9.
18. Davie SA, Maglione JE, Manner CK, Young D, Cardiff RD, MacLeod CL, et al. Effects of FVB/NJ and C57Bl/6 J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 2007;16:193-201.
19. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer. 1995;62:138-44.
20. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol. 2000;74:267-72.
21. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc Ser B (Stat Methodol). 2001;63:411-23.
22. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007;26:6577-92.
23. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 2005;92:2206-15.
24. Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Trope CG, et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol. 2003;91:160-72.
25. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003;9:2241-7.
26. Roy F, Laberge G, Douziech M, Ferland-McCollough D, Therrien M. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev. 2002;16:427-38.
27. Whiteman EL, Cho H, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab. 2002;13:444-51.
28. Mosca E, Barcella M, Alfieri R, Bevilacqua A, Canti G, Milanesi L. Systems biology of the metabolic network regulated by the Akt pathway. Biotechnol Adv. 2012;30:131-41.
29. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res. 2001;10:545-53.
30. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 2001;95:247-54.
31. Nadasi E, Anga B, Sandor J, Megyesi J, Kelemen D, Mottolese M, et al. Prognostic factors in Hungarian breast cancer patients. Anticancer Res. 2007;27:279-82.
32. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, et al. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012;17:766-74.
33. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004;64:3171-8.
34. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010;70:4260-4.
35. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004;4:551-61.
36. Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J Proteome Res. 2007;6:498-505.
37. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747-53.
38. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, Moore JH, et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010;11:446-50.
39. Goldstein DB. Common genetic variation and human traits. N Engl J Med. 2009;360:1696-8.
40. Bloom JS, Ehrenreich IM, Loo WT, Lite TL, Kruglyak L. Finding the sources of missing heritability in a yeast cross. Nature. 2013;494:234-7.
41. Gene Expression Omnibus accession number GSE54582. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54582 .
42. Storm P, Aits S, Puthia MK, Urbano A, Northen T, Powers S, et al. Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis. Oncogene. 2011;30:4765-79.
43. Taylor SL, Ganti S, Bukanov NO, Chapman A, Fiehn O, Osier M, et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol. 2010;298:F909-22.
44. Fiehn O, Wohlgemuth G, Scholz M. Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. In: Ludäscher B, Raschid L, editors. Data integration in the life sciences, lecture notes in computer science. San Diego: Springer-Verlag Berlin Heidelberg; 2005. p. 224-39.
45. Metabolomics Fiehn Lab. http://fiehnlab.ucdavis.edu/Metabolite-Library-2007/ .
46. Scholz M, Fiehn O. A public study design database for metabolomic projects. Pac Symp Biocomput. 2007;12:169-80.
47. Steinfath M, Groth D, Lisec J, Selbig J. Metabolite profile analysis: from raw data to regression and classification. Physiol Plant. 2008;132:150-61.
48. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0 - the human metabolome database in 2013. Nucleic Acids Res. 2013;41:D801-7.
49. Lopes CT, Franz M, Kazi F, Donaldson SL, Morris Q, Bader GD. Cytoscape Web: an interactive web-based network browser. Bioinformatics. 2010;26:2347-8.
50. Zhang ZD, Paccanaro A, Fu Y, Weissman S, Weng Z, Chang J, et al. Statistical analysis of the genomic distribution and correlation of regulatory elements in the ENCODE regions. Genome Res. 2007;17:787-97.
51. Gabriel KR. The biplot graphic display of matrices with application to principal component analysis. Biometrika. 1971;58:453-67.
52. Galindo M. An alternative for simultaneous representations. HJ-Biplot Qüestiió. 1986;10:13-23.
53. Vicente Villardón JL. MultBiplot: a package for multivariate analysis using biplots. Departamento de Estadística. Universidad de Salamanca; 2010. http://biplot.usal.es/ClassicalBiplot/index.html .
54. Parmar MKB, Cheung YB, Machin D. Survival analysis: a practical approach. 2nd ed. Chichester, England: John Wiley and Sons; 2007.
55. Do CB, Batzoglou S. What is the expectation maximization algorithm? Nat Biotechnol. 2008;26:897-9.
56. Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. Bioinformatics. 2003;19:889-90.
57. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241-7.